How Houston startups can hire top talent amid 'The Big Stay' trend of 2024

Guest column

Here are some tips to help startups and small businesses break through to candidates who are content in their current position or afraid to jump to a smaller business in today’s market. Photo by Tima Miroshnichenko from Pexels

Attracting “A-plus” talent when job candidates are favoring "The Big Stay” is a challenge for small businesses today. This is especially true when small businesses are competing with larger corporations for the same top talent.

To help startups and small businesses break through to candidates who are content in their current position or afraid to jump to a smaller business in today’s market, small businesses need to strategically position themselves as an attractive, viable alternative.

The following tips can help small businesses increase their appeal and attract top job candidates.

Employer branding

The employer brand or managing your reputation among job seekers and internal employees, plays a crucial part in attracting talent. Your internal workplace culture influences current employees and potential job candidates, but it also includes your digital presence. You want to ensure your digital footprint – website to social media – reflects your values, culture and successes. Your career page is a first impression for the job candidate. Including testimonials, day-in-the-life videos and clear job descriptions enhances the appeal of your organization.

Online reviews are another area that needs attention from an employer branding standpoint. Managing your reputation on review platforms like Glassdoor, Indeed and LinkedIn, exhibits how you address concerns and take any corrective action. It is also a barometer for many job candidates regarding employee satisfaction and potential areas for improvement.

Unique selling points

Your product or service has a unique selling point (USP) for customers and your company has a USP for talent. Small businesses usually trump larger corporations in flexibility and innovation. Small businesses can make quick decisions and employees can make a big impact on the company’s direction and success. When job candidates desire to make a substantial impact and have a more dynamic work environment, this is a definitive USP.

Learning and development programs that offer greater opportunity for leadership, cross-functional work and rapid advancement than your larger competitors can be appealing to top talent. Many high performers desire to move up the ranks and make a notable impact as quickly as possible, which is quickly attainable with startups and small businesses. The pathways to career advancement are many times less rigid in small business.

Compensation and benefits

Startups and small businesses usually cannot compete head-to-head with salaries, but there are a number of other ways to make your business more attractive to top talent. Starting off, you need to do your market research to ensure your compensation package is competitive, but other desirable benefits to consider include work-from-home or flex work options, health and wellness programs, financial wellness programs and robust retirement plans. Offering flexible benefits packages that can be tailored to meet the needs of employees at different life stages can be a considerable draw as well.

Candidate experience

When you are trying to recruit candidates who may be content with their current positions, it is important to make the application process as straightforward and clear as possible. This shows attention to detail, tells the candidate that you know what you want in an employee and it is respectful of their time. Once they apply, being responsive to their communication, establishing clear timelines and providing constructive feedback further elevates the candidate experience.

Referrals

Employees are your best recruiting tool. A personal referral speaks volumes since very few recommend candidates who would not fit the culture or the jobs available. Additionally, encouraging current employees to share their positive experiences with the company on social media can help cast a wider recruiting net.

Even though many employees are choosing to stay in their current roles, startups and small businesses can position themselves as attractive employers of choice. When you intentionally position yourself in an authentic manner, top-tier talent looking for career-growth opportunities, influence and meaningful work can be lured away from large competitors that may offer more traditional stability and name recognition.

------

Jaune Little is a director of recruiting services with Insperity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings